Phase 2 N=16 Soluble Epoxide Hydrolase Inhibition and Insulin Resistance
Diabetes Mellitus · Endocrine System Diseases · Glucose Metabolism Disorders
Primary: Insulin Sensitivity — 12.0; 11.6 mg/kg/FFM/min — p=0.71
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=9 IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer
Clinical Stage IV Gastric Cancer AJCC v8 · Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 · Clinical Stage IVA Gastric Cancer AJCC v8
Primary: Progression-free Survival — 1.1 Months
Phase 2 N=71 The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID)
SARS-CoV 2
Primary: Number of Participants That Achieve Virologic Clearance After Oral Administration of EIDD-2801 — 0; 4; 10; 7 Participants
Phase 2 N=23 Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL)
CLL · Leukemia
Primary: Number of Participants With a Response — 12 Participants
Phase 2 N=20 Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly Trabectedin Combined With Metronomic Cyclophosphamide
Soft-tissue Sarcomas
Primary: Phase I: Maximum Tolerated Dose (MTD) of Trabectedin When Administered in Association With CP. — 0.50 mg/m^2
Phase 2 N=27 The Effects of Patiromer on Serum Potassium Level and Gut Microbiome of ESRD Patients With Hyperkalemia
ESRD · Hyperkalemia · End Stage Renal Disease
Primary: Adverse Events of Participants Taking Patiromer in Lowering Serum Potassium Levels in End Stage Renal Disease (ESRD) Patients With Hyperkalemia Measured by…
Phase 2 N=20 A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer
Kidney Cancer
Primary: Percentage of Participants With Response — 0; 15; 65; 10 percentage of participants
Phase 2 N=242 Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016)
HIV-1 Infection
Primary: Number of Participants With ≥1 Adverse Event (AE) Through Week 36 — 66; 63; 36 Participants
Phase 2 N=20 Vitamin C Infusion for TReatment in Sepsis and Alcoholic Hepatitis
Alcoholic Hepatitis · Sepsis
Primary: Change in Model for End Stage Liver Disease (MELD) Score — -0.13; -2.9; -2.3; -2.4 score on a scale
Phase 2 N=62 Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment
Advanced Renal Cell Carcinoma · Metastatic Renal Cell Carcinoma
Primary: Progression Free Survival (PFS) — 7.5; 4.6; 6.8 Months
Phase 2 N=33 Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma
Lymphoma
Primary: Number of Participants With at Least One Dose Limiting Toxicity (DLT) — 3; 1; 0; 0 Participants
Phase 2 N=183 Safety & Efficacy of BCT197A2201 in COPD Patients Presenting With an Exacerbation
Chronic Obstructive Pulmonary Disease
Primary: Change in FEV1 From Baseline to Day 5 or Baseline to Day 10 Measure: FEV1 Change in Forced Expiry Volume in 1 Second — 155.1; 100.8; 48.9; 106.3 mL
Phase 2 N=65 Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas
Recurrent B-Cell Non-Hodgkin Lymphoma · Recurrent Chronic Lymphocytic Leukemia · Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
Primary: Proportion of Patients Who Achieve a Confirmed Response — 0.0800; 0; 0 proportion of responders
Phase 2 N=52 Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R
Leukemia
Primary: Disease-Free Survival at 2-Year Post-Transplant — 0.65 Proportion of pts alive in remission
Phase 2 N=28 Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer
Anatomic Stage IV Breast Cancer AJCC v8 · Metastatic Triple-Negative Breast Carcinoma · Prognostic Stage IV Breast Cancer AJCC v8
Primary: Progression-free Survival (PFS) — 4.8; 3.9; 8.2 Months